ANNEXON INC (ANNX)

Company Profile

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 84 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). The company is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). The company is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. The company has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Company Info

ANNEXON INC

1400 Sierra Point Parkway, Bldg C Suite 200

Brisbane California CALIFORNIA 94080

P: 16508225500

CEO: Douglas Love Esq.

Employees: 71

Website: https://annexonbio.com/